|
Originally published In Press as doi:10.1074/jbc.M907962199 on April 4, 2000
J. Biol. Chem., Vol. 275, Issue 24, 18061-18069, June 16, 2000
Oncostatin M and Transforming Growth Factor- 1 Induce
Post-translational Modification and Hyaluronan Binding to CD44 in
Lung-derived Epithelial Tumor Cells*
Joanna
Cichy § and
Ellen
Puré ¶
From the Wistar Institute, Philadelphia, Pennsylvania
19104, the § Institute of Molecular Biology,
Jagiellonian University, 31-120 Kraków, Poland, and the
¶ Ludwig Institute for Cancer Research, New York, New York
10158
Received for publication, September 30, 1999, and in revised form, April 3, 2000
 |
ABSTRACT |
CD44, a receptor for hyaluronan (HA), has been
implicated in tumor growth and metastasis. Most CD44-positive cells
fail to exhibit constitutive HA receptor function but CD44-mediated HA binding on hematopoetic cells can be induced by antibody cross-linking of the receptor and by physiologic stimuli, including cytokines. We now
demonstrate that oncostatin M (OSM) and transforming growth factor- 1, cytokines known to regulate the growth of tumor cells, stimulate HA binding in lung epithelial-derived tumor cells. In lung
epithelial-derived tumor cells, cytokine-induced binding resulted from
post-translational modification of the receptor. OSM-induced HA binding
was associated with a reduction in N-linked carbohydrate
content of CD44. In addition, OSM induced HA binding via a novel
mechanism requiring sulfation of chondroitin sulfate chains linked to
CD44. The mechanism underlying transforming growth factor- 1 induced
HA binding was distinct from the effects of OSM. The data presented
indicate that modulation of the glycosylation and sulfation of CD44 by
cytokines provides mechanisms for regulating cell adhesion during tumor
growth and metastasis.
 |
INTRODUCTION |
CD44 is a broadly distributed cell surface glycoprotein that can
mediate cell-cell adhesion and cell-matrix interactions (1-3). CD44 is
encoded by a single gene, but is expressed as multiple isoforms ranging
from 80 to 250 kDa. This structural diversity is generated by
alternative RNA splicing as well as differences in glycosylation and
the attachment of glycosaminoglycans
(GAGs)1 (4). The most common
form of CD44, referred to as standard or hematopoetic CD44 (CD44H),
does not contain any of the differentially spliced "variant" exons
(5). CD44 isoforms expressing variant exons have been demonstrated in
epithelia, activated lymphocytes, and tumor cells (4, 5).
CD44 is the principal receptor for hyaluronan (HA), a glycosaminoglycan
that is ubiquitously distributed in extracellular spaces (4, 6). The
HA-binding domain, located in the N-terminal region of CD44, is present
in all isoforms (7-9). The ubiquitous expression of HA and the
constitutive expression of CD44 by a wide variety of cells implies that
the interaction between these molecules is regulated. Indeed, most
primary CD44-positive cells fail to exhibit HA receptor function.
However, cross-linking of cell surface CD44 by some anti-CD44
monoclonal antibodies induces HA binding (4, 10). Variable
glycosylation, phosphorylation, cytoskeletal association, GAG
attachment, and expression of variant exons have all been implicated in
the constitutive and antibody-induced adhesion function of CD44
(11-15). Evidence has also been accumulating that CD44-mediated HA
binding can be induced by activation with physiologic stimuli including
cytokines (4, 16-18). However, with the exception of a single example
in which tumor necrosis factor- -induced activation of CD44 was
attributed to sulfation of a 90-kDa form of the receptor (19), the
mechanisms utilized by soluble factors to modulate CD44-HA binding
interactions remain unknown. Even in this case, the component of CD44
that was targeted for sulfation was not identified.
CD44 has been implicated in tumor growth and metastasis (20-24).
Transfection of cells originating from a non-metastatic tumor with a
CD44 cDNA isolated from a metastatic tumor cell line conferred metastatic behavior (25). Tumorigenic and metastatic proclivity of
human mammary carcinoma cell lines was shown to correlate with the
capacity of the tumor cells to internalize and degrade HA via CD44
(26). Moreover, the enhanced tumorigenesis of CD44-transduced lymphoma
and melanoma cells was found to be dependent on the ability of CD44 to
bind HA (27).
Despite compelling evidence to support the concept that CD44-HA
interactions play a role in tumorigenesis and metastasis, little is
known about how CD44-HA interactions are regulated in tumor cells. In
this study we investigated the effect of cytokines on the structure and
function of CD44 on lung carcinoma cells. This is of particular
interest because lung carcinomas represent a significant proportion of
all human tumors. We demonstrate that oncostatin M (OSM) and TGF- 1,
cytokines known to regulate the growth of tumor cells (27-30),
stimulate CD44-mediated HA binding in lung-derived epithelial tumor
cells. Furthermore, we defined some of the post-translational
modifications underlying the activation of CD44 adhesion function which
provides mechanisms for regulating cell adhesion during tumorigenesis
and/or metastasis.
 |
EXPERIMENTAL PROCEDURES |
Reagents and Antibodies--
Human recombinant OSM and human
recombinant TGF- 1 were purchased from R&D Systems (Minneapolis, MN).
The following anti-human CD44 mAbs were used (4): 5F12 that blocks HA
binding (a generous gift of Dr. B. F. Haynes, Duke University
Medical Center, Durham, NC) and F10-44 which enhances HA
binding, Hermes III, and G44-26 (PharMingen, San Diego, CA).
Purified hyaluronan from rooster comb (HA) was obtained from Sigma.
Purified HA from human umbilical cords (HA-ICN) was purchased from ICN
Biomedicals, Inc. (Costa Mesa, CA). The molecular weight of the
hyaluronan preparations were approximately 2.5 × 105
to 9 × 105 Da according to the manufacturer's
specifications. Fluorescein-conjugated rooster comb HA (FITC-HA) was
prepared as described (31). PE-labeled anti-human CD44 and anti-human
CD3 antibodies were purchased from PharMingen. Horseradish peroxidase
(HRP)-conjugated and alkaline phosphatase-conjugated anti-fluorescein
antibodies were obtained from Roche Molecular Biochemicals
(Indianapolis, IN). The fluorescent indicator calcein was purchased
from Molecular Probes Inc. (Eugene, OR). Recombinant
N-glycosidase F, O-glycosidase from
Diplococcus pneumoniae, and neuraminidase from
Athrobacter ureafaciens were all obtained from Roche
Molecular Biochemicals. Chondroitinase ABC from Proteus
vulgaris, chondroitinase AC and heparinase II from
Flavobacterium heparinum, keratanase from
Pseudomonas, and hyaluronate lyase from Streptomyces
hyalurolyticus were purchased from Sigma.
Cell Culture--
HTB58 human lung squamous carcinoma cell line,
HTB55 human lung adenocarcinoma, and Calu-6 anaplastic carcinoma were
obtained from the American Type Culture Collection (Rockville, MD).
Cells were cultured in Eagle's MEM (Biowhittaker, Walkersville, MD) supplemented with 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 50 µg/ml gentamycin (all from Life
Technologies, Inc., Grand Island, NY), and 10% fetal bovine serum
(FBS) (Atlanta Biologicals, Norcross, GA). Cells were plated, allowed
to grow to confluency, and treated with the indicated factors.
Flow Cytometry--
Cells were harvested using 0.2% EDTA or
trypsin/EDTA (0.05%, 0.02%) and stained with 5-10 µg/ml
PE-conjugated mouse anti-human CD44 antibody (G44-26) or PE-conjugated
anti-human CD3 antibody as an isotype-matched negative control. Cells
were then fixed with 3.7% formaldehyde and analyzed on a FACScan
(Becton Dickinson, Mansfield, MA). Soluble HA binding was assayed using
saturating amounts of FITC-HA. Specific binding of FITC-HA to CD44 was
determined by comparison of binding in the presence of blocking
anti-CD44 mAb 5F12 or an excess of unlabeled HA.
Cell Adhesion to Immobilized HA--
96-Well tissue culture
plates were coated with hyaluronan (ICN) at 1 mg/ml. Cells in
suspension (1 × 106/ml) were loaded with 5 µg/ml
calcein in HEPES-buffered saline for 30 min at 37 °C. After washing
in HEPES-buffered saline, labeled cells were resuspended in MEM
supplemented with 10% FBS and aliquoted into HA-coated wells. Plates
were then incubated for 30 min at 4 °C. Nonadherent cells were
removed by washing and adherent cells were quantified using a
fluorescence plate reader (Spectrafluor, SLT-Labinstruments Ges. m. b.
H., Salzburg, Austria).
Northern Blot Analysis--
Total RNA was isolated by SDS-phenol
extraction and resolved by electrophoresis in agarose gels containing
2.2 M formaldehyde, followed by capillary transfer to
Hybond-N membranes (Amersham Pharmacia Biotech). Filters were
hybridized with a 32P-labeled 1.4-kilobase
XhoI-XhoI restriction fragment of human CD44H
(5). The hybridization was carried out at 65 °C in 0.5 M
phosphate buffer, pH 7.0, containing 7% SDS, 1 mM EDTA, 10 mg/ml bovine serum albumin, and 100 µg/ml herring DNA. Blots were
washed at 65 °C in 40 mM phosphate buffer, pH 7.0, containing 1% SDS, 1 mM EDTA and exposed to x-ray film.
Western Blot Analysis--
Cells were lysed in PBS containing
1% Nonidet P-40, 0.1% sodium deoxycholate, and protease inhibitors
(0.2 units/ml aprotinin, 100 µg/ml leupeptin, and 1 mM
phenylmethylsulfonyl fluoride). Cell lysates were normalized based on
protein concentrations as determined using the BCA kit (Pierce,
Rockford, IL) and equal amounts of protein were subjected to
immunoprecipitation with anti-CD44 mAb (Hermes III) conjugated to
Sepharose. Immune complexes were washed once with lysis buffer followed
by three washes with PBS and resolved on SDS-7.5% PAGE under
nonreducing conditions. CD44 was visualized by enhanced
chemiluminescence (ECL) (Amersham Pharmacia Biotech) after
electrotransfer to a PVDF membrane (NEN Life Science Products Inc.,
Boston, MA) and incubation with mouse anti-CD44 antibodies (G44-26)
and donkey anti-mouse IgG antibodies conjugated to HRP. HA binding was
analyzed by ECL after incubation of PVDF bound CD44 with FITC-HA
followed by HRP-conjugated anti-fluorescein antibodies.
Enzymatic Digestion--
CD44 was immunoprecipitated with
Sepharose-conjugated anti-CD44 (Hermes III) mAb. CD44 was recovered
from beads by boiling for 5 min in the presence of 0.1% of SDS. After
addition of Triton X-100 (final concentration of 1%), affinity
purified CD44 was treated at 37 °C for 24 h with 40 units/ml
N-glycosidase F in 0.2 M sodium phosphate, pH
8.0, and 20 mM EDTA, or for 4 h with 100 milliunits/ml
neuraminidase in 50 mM sodium acetate, pH 5.5, containing 1 mM CaCl2 and 0.01% bovine serum albumin.
Treatment with chondroitin ABC (2 units/ml) and AC lyase (2 units/ml)
as well as keratanase (30 milliunits/ml), heparinase II (5 units/ml), and hyaluronate lyase (50 milliunits/ml) was performed on CD44 bound to
the Sepharose-conjugated Hermes III mAb in PBS at pH 7.4 (chondroitin
ABC and AC lyases, keratanase), PBS at pH 7.0 (heparinase), or in
buffer containing 50 mM sodium acetate, pH 5.2, and 125 mM NaCl (hyaluronate lyase), for 2 h at 37 °C.
Biosynthetic Labeling, Immunoprecipitation, and
Fluorography--
Cells were incubated in methionine-free medium
containing 2% FBS and 200 µCi/ml
[35S]methionine/cysteine (Trans35S-label), or
in sulfate-free MEM supplemented with 2% FBS and 500 µCi/ml
Na235SO4 (ICN). Cytokines were
added as indicated. Cells were lysed as for Western blot analysis.
Aliquots of [35S]methionine/cysteine-labeled cell lysates
were precleared with preimmune serum and then precipitated with
anti-CD44 mAb (Hermes III) conjugated to Sepharose. Immune complexes
were washed with high salt (0.6 M NaCl, 125 mM
KPO4, pH 7.4, 0.02% NaN3), mixed detergent
buffer (0.05% Nonidet P-40, 0.1% SDS, 0.3 M NaCl, 10 mM Tris, pH 8.6), and PBS. Aliquots of
Na235SO4-labeled cell lysates were
immunoprecipitated and washed as for Western blot analysis. CD44 was
then treated with enzymes or directly released by boiling in Laemmli
sample buffer and resolved on SDS-PAGE. Bands were detected by fluorography.
ELISA for HA Binding--
Cells were lysed and extracts were
subjected to immunoprecipitation with Sepharose-conjugated anti-CD44
(Hermes III) mAb. CD44 was then eluted from beads with 100 mM glycine, pH 2.5, and after neutralization to pH 7.0 with
Tris-HCl buffer, CD44 was quantified by ELISA. Hermes III mAb-coated
wells were used to capture CD44 and FITC-labeled G44-26 mAb and
FITC-labeled rooster comb HA were used to quantitate total CD44 and HA
binding, respectively. After incubation with alkaline
phosphatase-conjugated anti-FITC mAb, the reaction was developed with
p-nitrophenyl phosphate.
 |
RESULTS |
Cytokines Induce HA Binding in Lung-derived Epithelial Tumor
Cells--
Lung carcinomas represent a significant proportion of human
tumors. OSM and TGF- 1 are known to regulate the growth of tumor cells and the function of lung epithelial cells (27-30, 32, 33). We
found that OSM and TGF- 1 induced soluble HA binding to human squamous carcinoma-derived HTB58 cells (Fig.
1, A and B), and induced CD44-mediated adhesion of HTB58 cells to an HA-coated substrate
(Fig. 1C). HA binding was further increased on cells treated
with OSM plus TGF- 1. HA binding was CD44-mediated since it was
abrogated by the anti-CD44 mAb 5F12. The increase in HA binding could
not be attributed to increased levels of surface CD44 since no
significant increase in binding of anti-CD44 to cytokine-stimulated
cells was observed (Fig. 1A). Treatment of HTB58 cells with
hyaluronate lyase to remove endogenous HA increased HA binding capacity
to a similar extent in control and in OSM-stimulated cells and to a
lesser extent in TGF- -stimulated cells (data not shown). These data
indicate that CD44 may serve as an anchor for endogenous HA but argue
against the possibility that exogenously added HA binds to other
components in the pericellular matrix that are anchored by CD44. The
enhancement of HA binding induced by OSM and TGF- 1 was evident at
24 h and increased further at 48 h. Therefore, in subsequent
experiments cells were treated with cytokines for 48 h.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 1.
OSM and TGF- 1 induce
HA binding in HTB58 cells. A, flow cytometric analysis
of CD44 expression and soluble HA binding to HTB58 cells. Cells were
cultured for 24 h with 50 ng/ml OSM and/or 10 ng/ml TGF- 1.
Cells were labeled with FITC-HA and anti-CD44-PE mAbs and analyzed by
flow cytometry. The lines demarcate between negative and
positive reactivity based on staining with FITC-HA in the presence of
anti-CD44 mAb 5F12 and anti-CD3-PE, respectively. Numbers
indicated in the upper right quadrants represent the percent
positive cells. B, quantification of soluble HA binding.
Cells treated with cytokines as in A were stained with
FITC-HA. FITC-HA specific binding was calculated by subtracting
nonspecific binding in the presence of an excess of unlabeled HA and
analyzed by flow cytometry. Percent positive cells shown are from a
single representative experiment of five. C, binding of
HTB58 cells to immobilized HA. Cells treated with cytokines as in
A were loaded with calcein, seeded onto ICN-HA-coated
plates, and quantified using a fluorescence plate reader. Nonspecific
binding was determined by preincubation with anti-CD44 mAb 5F12 and
subtracted. The percentage of input cells bound is shown as the mean of
triplicate wells from two independent experiments ± S.D. The data
depicted in panels A, B, and C represent results
of independent experiments.
|
|
Cytokines Regulate the Post-translational Modification of
CD44--
Initial studies indicated that HA binding was evident in
cytokine-stimulated HTB58 cells, even if fixed with formaldehyde prior
to assaying. Furthermore, soluble CD44 spontaneously released from
cytokine-stimulated HTB58 cells exhibited enhanced HA binding compared
with unstimulated HTB58-derived soluble CD44 (data not shown).
Therefore, we hypothesized that structural modification of the
extracellular domain of CD44 was sufficient to mediate cytokine-enhanced HA binding. Cells of epithelial origin express the
standard form of CD44, but expression of variant isoforms of CD44 is
also a hallmark of epithelial cells (5). Three major CD44 RNA species
of approximately 1.6, 2.2, and 5 kilobases are characteristic for human
cells expressing only the standard form of CD44 (5). Transcripts of the
same electrophoretic mobility were detected in HTB58 cells. Although we
did not observe any significant increase in expression of CD44 at the
cell surface, stimulation of HTB58 cells with OSM or TGF- 1 did
up-regulate the steady state levels of the 1.6-, 2.2-, and 5-kilobase
CD44 mRNAs. Importantly, however, cytokine stimulation did not lead to the expression of alternatively spliced mRNAs encoding variant exon(s) (Fig. 2A).

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 2.
Molecular characterization of CD44 from HTB58
cells. Cells were treated with 50 ng/ml OSM and/or 10 ng/ml
TGF- 1 for 48 h. Total RNA was resolved by gel electrophoresis,
transferred to nylon membrane, and hybridized with
32P-labeled cDNA probe specific for human CD44H (5).
Similar amounts of 28 S and 18 S rRNA for each sample were visualized
by staining with ethidium bromide (bottom panel)
(A). CD44 from lysates of 35S-labeled cells
treated with cytokines as described in A was
immunoprecipitated with Sepharose-conjugated anti-CD44 mAb. Aliquots of
immune complexes were resolved on SDS-PAGE and immunoblotted for total
CD44 (B and C) or resolved on SDS-PAGE followed
by fluorography (D). Data shown in panel C
represent 10 times longer exposure of the blot depicted in panel
B. Molecular weight markers in kDa are indicated.
|
|
Two species of CD44 with average molecular mass of 90 and 180 kDa were
immunoprecipitated from detergent lysates of HTB58 cells (Fig.
2B). In addition to the predominant 90-kDa standard form, a
180-kDa form of CD44 has also been detected in hematopoetic cells
despite the fact that no expression of variant exons was detected (5).
Together with our data, these results are consistent with the 180-kDa
species arising from post-translational modification of the standard
form, including decoration with GAGs or dimerization of the standard
form, as previously suggested (5). Treatment with OSM alone or OSM plus
TGF- 1 resulted in faster migration of both the high and low
molecular weight forms of CD44 in HTB58 cells whereas TGF- 1 alone
appeared to slightly retard the migration of both species of CD44. The
OSM-induced decrease in the apparent molecular weight of CD44 resembled
that previously associated with reduced glycosylation (11).
Sulfation can facilitate functional interactions between adhesion
molecules, including L-selectin, and their ligands (34, 35). Recently, an increase in incorporation of sulfate into a 90-kDa
species in response to tumor necrosis factor- was suggested to
regulate the function of CD44 in a human leukemic cell line (19).
However, the component of CD44 that was inducibly sulfated was not
determined. Both the 90-kDa form and species of >210 kDa were detected
in anti-CD44 immunoprecipitates from lysates of sulfate-labeled HTB58
cells (Fig. 2D). The 90-kDa form of CD44 immunoprecipitated
from parallel cultures of unlabeled cells detected by immunoblotting
and the CD44 immunoprecipitated from [35S]sulfate-labeled
cells co-migrated. The highly sulfated high molecular weight species
exhibited extensive microheterogeneity with an average mass of >210
kDa compared to an average mass of 180 kDa for the high molecular
species detected by immunoblotting (Fig. 2) or
[35S]methionine biosynthetically labeled CD44. The
>210-kDa species was readily detectable by [35S]sulfate
labeling in anti-CD44 immunoprecipitates even following washing under
stringent conditions with high salt and mixed detergent buffers and was
detectable by immunoblotting when the blot was overexposed (Fig.
2C). These data indicate that the >210-kDa species was less
abundant although it was highly sulfated and therefore a major species
detected by [35S]sulfate labeling. Conversely, the more
abundant 180-kDa species of CD44 exhibited negligible sulfation.
Treatment with OSM resulted in a marked increase in sulfate
incorporation into CD44, particularly of the >210-kDa species while
treatment of HTB58 cells with TGF- 1 had only a slight effect on
incorporation of [35S]sulfate into CD44 (Fig.
2D). These data suggested that changes in sulfation are
potentially involved in regulating the HA binding function of CD44 in
OSM-stimulated lung-derived epithelial cells.
HA Binding of Isolated CD44--
Previously described assays
detect HA binding to the total repertoire of CD44 species expressed by
cells. To establish the biological significance of the differentially
modified forms of CD44, we developed a cell-free blot assay for
measuring HA binding to distinct species of CD44. Total cell lysates or
CD44 immunoprecipitated from detergent lysates were resolved by
SDS-PAGE. Proteins were transferred to PVDF membranes that were then
incubated with FITC-labeled HA followed by HRP-conjugated anti-FITC
antibodies. Reactivity was detected by ECL. To determine if HA binding
to isolated CD44 correlated with HA binding to intact cells, we
compared CD44-mediated HA binding to intact Calu-6, HTB55, and HTB58
cells by flow cytometry and to CD44 affinity purified from these cell
lines and evaluated in the cell-free blot assay. The three cell lines
expressed similar levels of CD44 but differed in their capacity to bind
HA (Fig. 3A); Calu-6 cells
constitutively bind HA, HTB55 cells do not bind HA, and HTB58 cells
exhibit an intermediate level of constitutive HA binding. In all three
cases, HA binding to isolated CD44 in the cell-free blot assay
correlated very well with HA binding to intact cells (Fig. 3,
A and B). The anti-CD44 antibody 5F12 and an
excess of unlabeled HA ablated the signal in the cell-free HA blot
assay (Fig. 3C), demonstrating the specificity of HA binding to isolated CD44. Furthermore, pretreatment of CD44 bound to PVDF membranes with an antibody, F10-44, that enhances HA binding to intact
cells (4) (data not shown), also augmented HA binding in the cell-free
blot assay (Fig. 3C). Thus HA binding of CD44 assayed in the
cell-free system mimicked the HA binding activity of intact cells.

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 3.
Comparison of HA binding by cell surface and
cell-free CD44. A, flow cytometric analysis of HA
binding to epithelial-like cell lines. Calu-6, HTB55, and HTB58 cells
were stained with PE-conjugated anti-CD44 Abs. Open
histograms in the left column represent profiles of a
negative control Ab (anti-CD3). Shaded areas in the
left column represent staining with anti-CD44 mAb. Ligand
binding was assayed by exposure of cells to FITC-HA (right
column, thick line). Nonspecific binding was determined by
pretreatment with blocking anti-CD44 mAb 5F12 followed by incubation
with FITC-HA (right column, thin line). B,
analysis of HA binding to detergent-solublized cell-free CD44 derived
from epithelial cell lines. Calu-6, HTB55, and HTB58 cells were lysed
and extracts were subjected to immunoprecipitation with
Sepharose-conjugated anti-CD44 mAb. One quarter of the immune complexes
was subjected to anti-CD44 immunoblot analysis whereas the remaining
three quarters was examined for HA binding. Samples were separated on
SDS-PAGE, transferred to PVDF membrane, and incubated with mouse
anti-human CD44 followed by HRP-conjugated anti-mouse Ab (left
panel) or FITC-HA followed by HRP-conjugated anti-FITC Ab
(right panel). Reactivity was then detected by ECL.
Molecular weight markers in kDa are indicated. C, effect of
HA blocking (5F12) and HA inducing (F10-44) antibodies on CD44-HA
interactions in HTB58 cells. Hermes III-immunoprecipitated CD44 was
resolved under nonreducing conditions on 7.5% preparative SDS-PAGE to
ensure equal loading of protein across the gel and transferred to PVDF
membrane. The membrane was then placed in a blotting manifold and the
various lanes incubated for 30 min at room temperature with unlabeled
rooster comb HA (HA RC), human umbilical cord HA (HA
ICN), or the indicated Abs, followed by incubation with FITC-HA.
HA binding was visualized by ECL after incubation with HRP-conjugated
anti-FITC Ab. D, analysis of HA binding in whole lysates
from HTB58 cells. Cells were treated for 48 h with 50 ng/ml OSM
and/or 10 ng/ml TGF- 1. Cell lysates were collected and equal amounts
of protein were subjected to anti-CD44 immunoblot analysis (left
panel) or the blot assay with FITC-HA (right
panel).
|
|
Using the cell-free blot assay we could discriminate binding to the
different species of CD44 expressed by HTB58 cells. Analysis of total
cell extracts of unstimulated cells did not reveal any reactivity with
HA. In contrast, prominent HA binding to a major 90-kDa species that
co-migrated with the predominant form of CD44 was evident in analysis
of whole cell lysates from OSM-stimulated HTB58 cells (Fig.
3D). When we enriched for CD44 by analyzing anti-CD44 immune
complexes, HA binding to both the 90-kDa and 180-kDa species of CD44
isolated from HTB58 cells was detected (Figs. 3 and 4). Furthermore,
treatment of HTB58 cells with OSM resulted in markedly increased HA
binding to both the low and high molecular weight forms of CD44 (Fig.
4). However, we did not detect any
significant difference in affinity of CD44 for HA in the cell-free blot
assay following TGF- 1 stimulation suggesting that OSM and TGF- 1
utilized different mechanisms for modulating CD44 receptor
function.

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 4.
Cytokines regulate glycosylation of
CD44. CD44 from lysates of HTB58 cells treated for 48 h with
50 ng/ml OSM and/or 10 ng/ml TGF- 1 was immunoprecipitated with
Sepharose-conjugated anti-CD44 mAb. One-third of immunoprecipitated
CD44 was left untreated, one-third was incubated with
N-glycosidase F (N-glyc F), and one-third with
neuraminidase. Each was then split into two groups and subjected to
anti-CD44 immunoblot analysis (A) or the blot assay with
FITC-HA (B). Molecular weight markers in kDa are
indicated.
|
|
The Role of Glycosylation in CD44-HA Interactions--
To
elucidate the role of carbohydrates in cytokine-induced HA binding,
HTB58 cells were subjected to metabolic or enzymatic deglycosylation
and analyzed for CD44-mediated HA binding by flow cytometry. Disruption
of N-linked glycosylation by exposure to tunicamycin was
found to inhibit CD44-HA interactions whereas treatment of cells with
neuraminidase, to cleave terminal sialic acid residues, markedly
enhanced the CD44-mediated constitutive binding of HA to intact HTB58
cells (Table I). Treatment with neuraminidase also enhanced HA binding of cytokine-stimulated cells but
to a lesser extent in OSM-treated cells then in cells stimulated with
TGF- 1. The effects of tunicamycin and neuraminidase were not due to
changes in the density of cell surface CD44 (Table I).
View this table:
[in this window]
[in a new window]
|
Table I
Effect of tunicamycin and neuraminidase on HA binding to HTB58 cells
Cells were cultured for 48 h in MEM containing 10% FBS and 1.5 µg/ml tunicamycin, 50 ng/ml OSM, and 10 ng/ml TGF- 1 as indicated.
At the end of the culture period, sialic acids were removed by
treatment with 100 milliunits/ml of neuraminidase when indicated for 40 min at 37 °C in HEPES-buffered saline. Cells were stained with
HA-FITC and anti-CD44-PE mAb and analyzed by flow cytometry. Data shown
are from a single representative experiment of three.
|
|
To determine the role of glycosylation in HA binding to isolated
receptor, CD44 immunoprecipitated from lysates of HTB58 cells was
subjected to digestion with N-glycosidase F or
neuraminidase. The apparent molecular mass of both the 90- and 180-kDa
species of CD44 was reduced by treatment with N-glycosidase
F to 70 and 150 kDa, respectively (Fig. 4A). Furthermore,
treatment with N-glycosidase F eliminated the differences in
mobility of both species of CD44 isolated from control and OSM-treated
cells. Thus, the more rapid migration of CD44 induced by OSM could at
least partly be attributed to modification of N-linked
carbohydrate moieties. Neuraminidase induced a more modest reduction in
the apparent molecular weight of the receptor, but CD44
immunoprecipitated from OSM-stimulated cells still migrated somewhat
more rapidly than CD44 from unstimulated cells following treatment with neuraminidase.
Consistent with the results obtained with tunicamycin-treated cells,
enzymatic deglycosylation of N-linked carbohydrates from isolated CD44 abrogated HA binding. Also similar to intact cells, hydrolysis of sialic acids augmented CD44-HA interactions of both the
90- and 180-kDa isoforms of CD44 immunoprecipitated from either control
or cytokine-stimulated cells (Fig. 4, A and B).
The binding of HA to neuraminidase-treated CD44 was blocked by an
excess of unlabeled rooster comb or human umbilical cord HA as well as
by 5F12 antibody (data not shown). When N-glycosidase F and
neuraminidase were given together, the enhancement of HA binding
induced by neuraminidase was no longer evident, suggesting that sialic
acid residues of N-linked oligosaccharide chains are
involved in inhibition of CD44 receptor function.
The Role of Sulfation in Cytokine-stimulated HA Binding Activity of
CD44--
As described above, sulfated CD44 species of 90 kDa and high
molecular mass forms of >210 kDa were detected in HTB58 cells (Fig.
5). The higher molecular weight form was
consistently the major sulfated form of CD44, particularly after OSM
stimulation. The 90-kDa band from lysates of
[35S]sulfate-labeled cells stimulated with OSM was
somewhat more intense than in untreated cells, but this most likely
resulted from an increase in synthesis of CD44 rather than an increase in the incorporation of sulfate groups on a molar basis, since the
ratio of [35S]methionine to [35S]sulfate
incorporated in OSM-treated cells was similar to that of control cells
(Table II). In contrast, OSM given alone
or in combination with TGF- 1 dramatically increased the ratio of
sulfate to methionine incorporated into the >210-kDa form.

View larger version (63K):
[in this window]
[in a new window]
|
Fig. 5.
Chlorate inhibits sulfation of CD44.
HTB58 cells were cultured in the absence or presence of 40 mM sodium chlorate for 48 h. Cells were then incubated
for 48 h in sulfate-free MEM containing 2% FBS, 500 µCi/ml
Na235SO4, and 40 mM
sodium chlorate, 50 ng/ml OSM, and 10 ng/ml TGF- 1 as indicated. CD44
was immunoprecipitated with Sepharose-conjugated anti-CD44 mAb. The
immune complexes were subjected to anti-CD44 immunoblot (A)
and cell-free HA blot analysis (B). The remaining
35S-labeled immune complexes were resolved on SDS-PAGE
followed by fluorography (C). Data shown in D
represent 10 times longer exposure of the data shown in the right
panel of C. Molecular weight markers in kDa are
indicated.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Comparison of [35S]methionine and [35S]sulfate
incorporation into CD44 in HTB58 cells
Untreated cells or cells stimulated with 50 ng/ml OSM and/or 10 ng/ml
TGF- 1 for 48 h were labeled with
Na235SO4 or [35S]methionine. CD44 was
then immunoprecipitated with Sepharose-conjugated anti-CD44 mAb and
subjected to SDS-PAGE. Gels were impregnated with EN3HANCE (NEN
Life Science Products Inc), exposed to a PhosphorImager screen and the
resulting image was scanned. Numbers indicate the relative intensities
of the 90-kDa (left) and 180- to >210-kDa (right) species. Results
are expressed as an average of three to four independent
experiments ± S.D.
|
|
To determine whether sulfation was required for the adhesion of CD44 to
HA, HTB58 cells were incubated in the presence of sodium chlorate
(NaClO3). Treatment of cells with NaClO3
inhibited the incorporation of sulfate into the 90- and >210-kDa forms
of CD44 without affecting the synthesis or cell surface expression of
CD44 (Fig. 5 and data not shown). Chlorate did not decrease the
capacity of control or TGF- 1-stimulated cells to bind HA but
markedly compromised OSM-induced HA binding (Fig.
6A). These results establish
that sulfation of CD44 is an important mechanism underlying OSM-induced
HA binding to intact cells. However, chlorate did not affect HA binding
to isolated CD44 in the cell-free blot assay (Fig. 5B).
Therefore, OSM appears to induce HA binding via two mechanisms, one
involving sulfation and the other glycosylation. These results suggest
that the OSM-induced HA binding to cell-free CD44 is more likely
dependent on the differential glycosylation than on sulfation described
above. These results also indicate that the enhancement of HA binding
mediated by sulfation is only evident under nondenaturing conditions
and/or that association of low and high molecular weight forms of CD44
is required for the sulfation-dependent function of CD44.
To test this hypothesis we performed a "functional" ELISA to
measure HA binding of detergent-solublized CD44 (Fig. 6B).
The total CD44 immunoprecipitated using anti-CD44 mAb conjugated to
Sepharose was eluted from beads and captured on anti-CD44-coated wells.
The levels of CD44 and HA binding were quantitated by ELISA (Fig.
6B). Since immunoprecipitated CD44 contains both low and
high molecular weight isoforms, the activity of CD44 determined by this
assay reflects the binding of the combination of both forms compared
with the blotting assay that discriminates between HA binding to each
isoform separated by SDS-PAGE. OSM given alone or together with
TGF- 1, but not TGF- 1 alone, significantly enhanced HA binding as
measured in the ELISA. Furthermore, chlorate partially inhibited the
OSM-induced HA binding detected in the ELISA (Fig. 6B),
suggesting that both sulfation-dependent and -independent
mechanisms are involved in HA binding of cell-free CD44 derived from
OSM-stimulated cells.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 6.
Sulfation of CD44 is required for optimal
OSM-induced HA binding to intact HTB58 cells and cell-free CD44.
A, flow cytometric analysis of HA binding. HTB58 cells were
incubated in the absence or presence of 40 mM sodium
chlorate for 48 h. Cells were then treated for an additional
48 h with 40 mM sodium chlorate, 50 ng/ml OSM, and 10 ng/ml TGF- 1 as indicated. Cells were stained with FITC-HA in the
presence or absence of anti-CD44 5F12 mAb. Percentage of positive cells
is shown as the mean ± S.D. from four independent experiments.
B, ELISA of HA binding by detergent-solublized CD44. HTB58
cells treated as in A were lysed and extracts were subjected
to immunoprecipitation with Sepharose-conjugated anti-CD44 mAb. CD44
was then eluted from beads and quantified by ELISA. The data are shown
as the mean of triplicate wells from three experiments ± S.D. The
difference between chlorate-untreated and chlorate-treated cells was
statistically significant (Student's t test
p < 0.001) only in samples containing OSM.
|
|
To characterize the target of sulfation, CD44 immunoprecipitated from
[35S]sulfate-labeled cells was subjected to digestion
with glycosidases or enzymes which cleave different GAGs. Removal of
N-linked carbohydrates by N-glycosidase F and
sialic acids by neuraminidase as well as treatment with
O-glycosidase after removal of sialic acids had no effect on
sulfation of either the 90- or >210-kDa forms (data not shown).
Digestion of CD44 with keratanase or hyaluronate lyase did not reduce
the sulfation of CD44 and treatment of CD44 with heparinase II which
reduced the molecular mass of the 90- and >210-kDa forms did not
significantly decrease the degree of sulfation of the receptor (data
not shown). However, chondroitin ABC and chondroitin AC lyase digestion
of CD44 immunoprecipitated from HTB58 cells reduced the apparent
molecular mass of the 90- and 180-kDa forms of CD44 (Fig.
7, B and C) and
resulted in the release of sulfate from the high molecular weight
species of CD44 (Fig. 7A). Thus the extensive sulfation
associated with the high molecular weight form of CD44 is mainly due to
modification with chondroitin sulfate chains.

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of chondroitin ABC and chondroitin AC
lyases on sulfation of CD44 in HTB58 cells. CD44 from lysates of
HTB58 cells treated for 48 h with 50 ng/ml OSM and/or 10 ng/ml
TGF- 1 in the presence of
Na235SO4 (A) or
[35S]methionine (B) was immunoprecipitated
with Sepharose-conjugated anti-CD44 mAb. One-third of
immunoprecipitated CD44 was left untreated, one-third was incubated
with chondroitinase ABC (chondro ABC), and one-third with
chondroitinase AC (chondro AC). CD44 was then examined on
7.5% (A) or gradient (5-16%) SDS-PAGE (B)
followed by fluorography. CD44 from lysates of unlabeled HTB58 cells
treated for 48 h with 50 ng/ml OSM and/or 10 ng/ml TGF- 1 was
immunoprecipitated with Sepharose-conjugated anti-CD44 mAb and
subjected to treatment with chondroitinases as above. CD44 was then
subjected to anti-CD44 immunoblot analysis (C).
|
|
The highly sulfated species of CD44 of >210 kDa were enriched in cells
stimulated with OSM (Figs. 5 and 7). Although less prominent following
treatment with chlorate, we could still detect the >210-kDa species of
CD44 in cells treated with OSM with prolonged exposure to film (Fig. 5,
panel D). Therefore, we conclude that although OSM may
induce an increase in the length or number of chondroitin sulfate
chains attached, OSM also induces an increase in the incorporation of
sulfate into the chondroitin sulfate attached to CD44.
 |
DISCUSSION |
The formation of metastatic deposits requires modulation of the
adhesiveness of tumor cells, allowing them to disseminate through the
bloodstream and lymphatics from their site of origin to distal sites.
The accumulation of HA is often increased around colonies of metastatic
cells due to secretion of high levels of HA by tumor or stromal cells
(27). The importance of regulated HA binding is evidenced by the fact
that CD44 mutants that do not bind HA fail to promote growth and
metastasis of some tumors (26). Our data demonstrate that OSM and
TGF- 1 augment HA binding in tumor-derived HTB58 cells. Both OSM and
TGF- 1 were previously shown to regulate the growth of tumor cells
(27-30). Taken together these data suggest that OSM and TGF- 1 may
be important in modulating tumor growth and metastasis by regulating HA
binding activity. These studies add OSM and TGF- 1 to a network of
soluble factors that regulate CD44-HA interactions (4, 16, 17) and
provide the first example of cytokine regulation of the affinity of
CD44 on epithelial-derived tumor cells.
Modification of the sugar moieties of CD44 has previously been
suggested as a mechanism for regulating affinity of the receptor for HA
(11-13, 36). Depending on the cell type in which CD44 was expressed or
on the experimental approach used, including deglycosylation of surface
proteins or hydrolysis of carbohydrates from soluble
CD44-immunoglobulin chimeric proteins, N-deglycosylation was
demonstrated to either abrogate or augment HA binding to intact cells,
whereas removal of sialic acids was found to either augment or have no
effect on HA binding. However, these studies did not reveal whether the
observed changes in CD44 function were due to deglycosylation of CD44
or deglycosylation of other molecule(s) on the cell surface which may
cooperate with CD44 to regulate HA binding function. Likewise,
interpretation of previous results obtained using recombinant soluble
CD44-immunoglobulin chimeric proteins was complicated by the fact that
glycosylation occurs in a cell-specific manner and therefore the
structure of oligosacharides decorating CD44-immunoglobulin fusion
proteins is largely dependent on the transfected cells expressing the
chimeric transgene. In addition, these approaches could not clarify the
contribution of different CD44 isoforms to HA binding in cells that
express multiple isoforms of CD44. The cell-free HA blotting assay
described herein allowed us to evaluate the HA binding activity of each of multiple species of CD44 expressed on a single cell type. We demonstrated that the 90-kDa as well as the high molecular mass 180-kDa
species of CD44 expressed on HTB58 cells bind HA. Furthermore, we
established a direct correlation between alterations in the glycosylation of CD44 and its HA binding activity. Thus, in the absence
of any cell surface constraints, removal of N-linked
carbohydrates abrogated HA binding to both the 90- and 180-kDa forms of
CD44, whereas removal of sialic acids augmented their affinity for HA. The fact that HA binding to the highest molecular mass species of >210
kDa was not detectable once the anti-CD44 immune complexes were
resolved by SDS-PAGE may indicate a requirement for cooperativity between the multiple forms of the receptor for HA binding to the highest molecular mass form. However, we cannot rule out a low level of
HA binding to this form, below the level of detection of the HA blot
assay. In addition, our data indicate that HA binding induced by OSM
was associated with a decrease in N-linked carbohydrate content and optimal OSM-induced HA binding required sulfation of
proteoglycan forms of CD44. The mechanism(s) by which TGF- 1 induced
HA binding is clearly distinct from those involved by stimulation with
OSM. In initial studies of TGF- 1-stimulated HTB58 cells we found
that TGF- 1 induced accumulation of a species of CD44 that exhibits
altered migration upon isoelectrofocusing similar to that induced by
neuraminidase treatment (data not shown). Thus TGF- 1-enhanced HA
binding to HTB58 cells may be partially due to decreased sialylation of
CD44. The fact that in contrast to the cell-bound receptor, enhanced HA
binding was not observed for cell-free CD44 derived from TGF- 1
treated cells may indicate that association with other molecules,
facilitated by TGF- 1-mediated desialylation of CD44, is required for
TGF- 1-enhanced HA binding function.
Consistent with the role of sulfation of OSM-induced HA binding to
epithelial-derived tumor cells established in this study, a recent
study of a human leukemic cell line, SR91, also suggested a role for
sulfation in regulating the HA binding function of CD44 (19). However,
in that case a single species of CD44 with an apparent molecular mass
of 90 kDa was detected and tumor necrosis factor- increased the
sulfation of this form. Our data indicate that an increase in sulfation
of the higher molecular form of CD44, which was attributed to the
presence of chondroitin sulfate chains, mainly accounted for the
enhancement in HA binding in OSM-treated HTB58 cells. Furthermore, our
data obtained with CD44 isolated from chlorate-treated HTB58 cells
indicate that an increase in sulfation of CD44 per se rather
than other cell surface molecules is likely responsible for the effect
of OSM. Interestingly, the apparent discrepancy between the requirement
for sulfation in the ELISA and blot assays suggests that the
sulfation-dependent HA binding function of CD44 may involve
cooperativity of the low and high molecular forms of CD44. Since in
OSM-treated HTB58 cells the adhesion of CD44 to HA is partially
dependent upon an increase in the extent of sulfation of the
chondroitin sulfate chains attached to the receptor and only a small
fraction of the total CD44 appears to be decorated by GAG, we propose
that highly sulfated chondroitin sulfate chains may facilitate
oligomerization of the receptor and ultimately HA binding. In this
regard, it is interesting to note that CD44 has been shown to recognize
and bind several molecules modified by chondroitin sulfate chains,
including serglycin and the invariant chain of class II MHC molecules
(37, 38). More recently, alternatively spliced CD44 isoforms were
reported to promote cellular adhesion through the recognition of
chondroitin sulfate-modified CD44, which may imply a role of the
chondroitin sulfate chains in receptor oligomerization (39).
In summary, our results demonstrate that cytokines regulate the
adhesion function of CD44 on epithelial-derived tumor cells. Furthermore, we established that various cytokines utilize different mechanisms to regulate the transition of CD44 from the low to the high
affinity state, including differential glycosylation and a novel
mechanism involving sulfation of the chondroitin sulfate chains
attached to CD44.
 |
ACKNOWLEDGEMENTS |
We thank Dr. C. Cuff, Dr. M. Jacob, A. Mani,
and Dr. D. Speicher for review of the manuscript.
 |
FOOTNOTES |
*
This work was supported by a fellowship from the Cancer
Research Institute (to J. C.) and a grant from the Arthritis
Foundation (to E. P.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, April 4, 2000, DOI 10.1074/jbc.M907962199
 |
ABBREVIATIONS |
The abbreviations used are:
GAG, glycosaminoglycan;
HA, hyaluronan;
OSM, oncostatin M;
TGF- 1, transforming growth factor- 1;
CD44H, standard CD44;
FITC, fluorescein isothiocyanate;
HRP, horseradish peroxidase;
MEM, minimal
essential medium;
FBS, fetal bovine serum;
PBS, phosphate-buffered
saline;
mAb, monoclonal antibody;
PAGE, polyacrylamide gel
electrophoresis;
PVDF, polyvinylidene difluoride;
ELISA, enzyme-linked immunosorbent assay;
PE, phycoerythrin..
 |
REFERENCES |
| 1.
|
Goldstein, L. A.,
Zhou, D. F. H.,
Picker, L. J.,
Minty, C. N.,
Bargatze, R. F.,
Ding, J. F.,
and Butcher, E. C.
(1989)
Cell
56,
1063-1072
|
| 2.
|
Stamenkovic, I.,
Amiot, M.,
Pesando, J. M.,
and Seed, B.
(1989)
Cell
56,
1057-1062
|
| 3.
|
Jalkanen, S.,
Jalkanen, M.,
Bargatze, R.,
Tammi, M.,
and Butcher, E. C.
(1988)
J. Immunol.
141,
1615-1623
|
| 4.
|
Schlossman, S.,
Boumsell, L.,
and Gilks, W.
(1995)
White Cell Differentiation Antigens
, Oxford University Press, New York
|
| 5.
|
Stamenkovic, I.,
Aruffo, A.,
Amiot, M.,
and Seed, B.
(1991)
EMBO J.
10,
343-348
|
| 6.
|
Aruffo, A.,
Stamenkovic, I.,
Meinich, M.,
Underhill, C. B.,
and Seed, B.
(1990)
Cell
61,
1303-1313
|
| 7.
|
Liao, H.-X.,
Lee, D. M.,
Levesque, M. C.,
and Haynes, B. F.
(1995)
J. Immunol.
155,
3938-3945
|
| 8.
|
Peach, R. J.,
Hollenbaugh, D.,
Stamenkovic, I.,
and Aruffo, A.
(1993)
J. Cell Biol.
122,
257-264
|
| 9.
|
Bajorath, J.,
Greenfield, B.,
Munro, S. B.,
Day, A. J.,
and Aruffo, A.
(1998)
J. Biol. Chem.
273,
338-343
|
| 10.
|
Lesley, J.,
Kincade, P. W.,
and Hyman, R.
(1993)
Eur. J. Immunol.
23,
1902-1909
|
| 11.
|
Katoh, S.,
Zheng, Z.,
Oritani, K.,
Shimozato, T.,
and Kincade, P.
(1995)
J. Exp. Med.
182,
419-429
|
| 12.
|
Lesley, J.,
English, N.,
Perschl, A.,
Gregoroff, J.,
and Hyman, R.
(1995)
J. Exp. Med.
182,
431-437
|
| 13.
|
Skelton, T. P.,
Zeng, C.,
Nocks, A.,
and Stamenkovic, I.
(1998)
J. Cell Biol.
140,
431-446
|
| 14.
|
Puré, E.,
Camp, R. L.,
Peritt, D.,
Panettieri, R. A.,
Lazaar, A. L.,
and Nayak, S.
(1995)
J. Exp. Med.
181,
55-62
|
| 15.
|
Esford, L. E.,
Maiti, A.,
Bader, S. A.,
Tufaro, F.,
and Johnson, P.
(1998)
J. Cell Sci.
111,
1021-1029
|
| 16.
|
Levesque, M. C.,
and Haynes, B. F.
(1996)
J. Immunol.
156,
1557-1565
|
| 17.
|
Lazaar, A. L.,
Albelda, S. M.,
Pilewski, J. M.,
Brennan, B.,
Puré, E.,
and Panettieri, R. A.
(1994)
J. Exp. Med.
180,
807-816
|
| 18.
|
Murakami, S.,
Miyake, K.,
June, C. H.,
Kincade, P. W.,
and Hodes, R. J.
(1990)
J. Immunol.
145,
3618-3627
|
| 19.
|
Maiti, A.,
Maki, G.,
and Johnson, P.
(1998)
Science
282,
941-943
|
| 20.
|
Thomas, L.,
Byers, R. H.,
Vink, J.,
and Stamenkovic, I.
(1992)
J. Cell Biol.
118,
971-977
|
| 21.
|
Schmits, R.,
Filmus, J.,
Gerwin, N.,
Senaldi, G.,
Kiefer, F.,
Kundig, T.,
Wakeham, A.,
Shahinian, A.,
Catzavelos, C.,
Rak, S.,
Rak, J.,
Furlonger, C.,
Zakarian, A.,
Simard, J. L.,
Ohashi, P. S.,
Paige, C. J.,
Gutierrez-Ramos, J. C.,
and Mak, T. W.
(1997)
Blood
90,
2217-2233
|
| 22.
|
Yeo, T. K.,
Nagy, J. A.,
Yeo, K. T.,
Dvorak, H. F.,
and Toole, B. P.
(1996)
Am. J. Pathol.
148,
1733-1740
|
| 23.
|
Ladeda, V.,
Aguirre Ghiso, J. A.,
and Bal de Kier Joffe, E.
(1998)
Exp. Cell Res.
242,
515-527
|
| 24.
|
Bartolazzi, A.,
Peach, R.,
Aruffo, A.,
and Stamenkovic, I.
(1994)
J. Exp. Med.
180,
53-66
|
| 25.
|
Gunthert, U.,
Hofmann, M.,
Rudy, W.,
Reber, S.,
Zoller, M.,
Haubmann, I.,
Matzku, S.,
Wenzel, A.,
Ponta, H.,
and Herrlich, P.
(1991)
Cell
65,
13-24
|
| 26.
|
Yu, Q.,
Toole, B. P.,
and Stamenkovic, I.
(1998)
J. Exp. Med.
186,
1985-1996
|
| 27.
|
Naot, D.,
Sionov, R. V.,
and Ish-Shalom, D.
(1997)
Adv. Cancer Res.
71,
241-319
|
| 28.
|
Malik, N.,
Kallestad, J. C.,
Gunderson, N. L.,
Austin, S. D.,
Newbauer, M. G.,
Ochs, V.,
Marquardt, H.,
Zarling, J. M.,
Shoyab, M.,
Wei, C-M.,
Linsley, P. S.,
and Rose, T. M.
(1989)
Mol. Cell. Biol.
9,
2847-2853
|
| 29.
|
Brown, T. J.,
Lioubin, M. N.,
and Marquardt, H.
(1987)
J. Immunol.
139,
2977-2983
|
| 30.
|
Murakami-Mori, K.,
Taga, T.,
Kishimoto, T.,
and Nakamura, S.
(1995)
J. Clin. Invest.
96,
1319-1327
|
| 31.
|
De Belder, A. N.,
and Wik, K. O.
(1975)
Carbohydr. Res.
44,
251-257
|
| 32.
|
Cichy, J.,
Potempa, J.,
Chawla, R. K.,
and Travis, J.
(1995)
J. Clin. Invest.
95,
2729-2733
|
| 33.
|
Cichy, J.,
Rose-John, S.,
and Puré, E.
(1998)
FEBS Lett.
429,
412-416
|
| 34.
|
Sako, D.,
Comess, K. M.,
Barone, K. M.,
Camphausen, R. T.,
Cumming, D. A.,
and Shaw, G. D.
(1995)
Cell
83,
323-331
|
| 35.
|
Pouyani, T.,
and Seed, B.
(1995)
Cell
83,
333-343
|
| 36.
|
Bartolazzi, A.,
Nocks, A.,
Aruffo, A.,
Spring, F.,
and Stamenkovic, I.
(1996)
J. Cell Biol.
132,
1199-1208
|
| 37.
|
Naujokas, M. F.,
Morin, M.,
Anderson, M. S.,
Peterson, M.,
and Miller, J.
(1993)
Cell
74,
257-268
|
| 38.
|
Toyama-Sorimachi, N.,
and Miyasaka, M.
(1994)
Int. Immunol.
6,
655-660
|
| 39.
|
Chiu, R. K.,
Droll, A.,
Dougherty, S. T.,
Carpenito, C.,
Cooper, D. L.,
and Dougherty, G. J.
(1999)
Exp. Cell Res.
248,
314-321
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Iwase, R. Shen, D. Navarro, and D. M. Nanus
Direct Binding of Neutral Endopeptidase 24.11 to Ezrin/Radixin/Moesin (ERM) Proteins Competes with the Interaction of CD44 with ERM Proteins
J. Biol. Chem.,
March 19, 2004;
279(12):
11898 - 11905.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Cichy, R. Bals, J. Potempa, A. Mani, and E. Pure
Proteinase-mediated Release of Epithelial Cell-associated CD44. EXTRACELLULAR CD44 COMPLEXES WITH COMPONENTS OF CELLULAR MATRICES
J. Biol. Chem.,
November 8, 2002;
277(46):
44440 - 44447.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Delcommenne, R. Kannagi, and P. Johnson
TNF-{alpha} increases the carbohydrate sulfation of CD44: induction of 6-sulfo N-acetyl lactosamine on N- and O-linked glycans
Glycobiology,
October 1, 2002;
12(10):
613 - 622.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Brown, A. Maiti, and P. Johnson
Role of Sulfation in CD44-Mediated Hyaluronan Binding Induced by Inflammatory Mediators in Human CD14+ Peripheral Blood Monocytes
J. Immunol.,
November 1, 2001;
167(9):
5367 - 5374.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. D. Camenisch and J. A. McDonald
Hyaluronan . Is Bigger Better?
Am. J. Respir. Cell Mol. Biol.,
October 1, 2000;
23(4):
431 - 433.
[Full Text]
|
 |
|

|
 |

|
 |
 
J. M. Chong and D. W. Speicher
Determination of Disulfide Bond Assignments and N-Glycosylation Sites of the Human Gastrointestinal Carcinoma Antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM)
J. Biol. Chem.,
February 16, 2001;
276(8):
5804 - 5813.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|